查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595030

前列腺癌診斷的全球市場

Prostate Cancer Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球前列腺癌診斷市場預計將達到 137 億美元

全球前列腺癌診斷市場預計 2023 年為 58 億美元，預計到 2030 年將達到 137 億美元，2023 年至 2030 年複合年成長率為 13.1%。初步測試是本報告分析的細分市場之一，預計複合年成長率為 12.4%，到分析期結束時將達到 100 億美元。在分析期間，驗證性測試領域的複合年成長率預計為 15.2%。

美國市場預計15億美元，中國預計複合年成長率16.9%

到 2023 年，美國前列腺癌診斷市場預計將達到 15 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達33億美元，2023-2030年分析期間複合年成長率為16.9%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 9.2% 和 10.8%。在歐洲，德國預計複合年成長率為 10.0%。

全球前列腺癌診斷市場—主要趨勢和促進因素總結

什麼是攝護腺癌診斷藥物？

前列腺癌診斷是指用於檢測、診斷和監測男性前列腺癌的方法和技術。這些診斷方法對於早期發現前列腺癌至關重要，以便及時介入和更有效的治療。最常見的診斷方法包括前列腺特異性抗原 (PSA) 血液檢測、直腸指檢 (DRE) 以及先進的影像技術，例如 MRI 和超音波。此外，通常會進行切片檢查來確認診斷並確定癌症的階段。由於前列腺癌是男性最常見的癌症之一，早期準確的診斷對於提高存活率和有效管理治療計劃至關重要。

隨著人們對前列腺癌的認知不斷提高，尤其是老年男性和有明顯家族病史的高風險族群，可靠診斷的需求不斷成長。透過提供準確和及時的診斷，前列腺癌診斷不僅有助於快速開始治療，而且還支持監測治療後的疾病進展和復發。早期發現可以擴大治療選擇，並且可以顯著降低死亡率。隨著人口老化和前列腺癌盛行率的增加，對先進診斷工具的需求增加，使前列腺癌診斷市場成為現代醫療保健的重要組成部分。

科技進步將如何改變前列腺癌診斷藥物？

分子診斷、診斷影像和人工智慧 (AI) 的技術進步正在徹底改變前列腺癌的診斷，使診斷更加準確、侵入性更小、更快。分子診斷測試，例如基因和生物標記測試，擴大用於檢測與前列腺癌相關的特定基因突變和蛋白質標記。這些測試有助於確定患者的風險水平，並用於指南個人化治療決策，使臨床醫生能夠根據癌症的個別特徵制定治療方案。例如，PCA3 測試和 4Kscore 測試等測試收集尿液或血液來檢測特定的生物標記物，這可以幫助風險評估並減少侵入性切片檢查的需要。

先進的影像技術，例如多參數 MRI 和 PET 掃描，可提供高度詳細的影像，可以比傳統方法更準確地檢測前列腺癌。這些技術可以實現更精確的切片檢查目標，這有助於更準確的癌症分期，這對於制定有效的治療計劃至關重要。此外，人工智慧和機器學習演算法擴大用於分析來自影像檢查和基因測試的大型資料集，透過識別人類觀察可能遺漏的模式來提高診斷準確性。事實證明，人工智慧驅動的診斷在風險評估、預測疾病進展和監測治療反應方面也很有用。這些技術共同正在改變前列腺癌診斷市場，實現早期檢測、個人化醫療和改善病患治療效果。

為什麼患者和臨床醫生擴大採用先進的前列腺癌診斷方法？

由於具有更早、更準確的檢測、更少的侵入性和個人化治療選擇的潛力，患者和臨床醫生擴大採用先進的前列腺癌診斷方法。 PSA 檢測和 DRE 等傳統診斷方法的特異性和敏感性有限，常常導致假陽性和不必要的切片檢查。分子測試和 MRI 標靶切片檢查等先進診斷方法可提供有關癌症風險和分期的更準確資訊，使臨床醫生能夠就患者治療做出更明智的決策。這對於早期或緩慢進展的癌症患者尤其重要，因為它允許主動監測而不是立即干涉，從而減少過度治療副作用的可能性。

對於患者來說，先進的診斷方法可以提供更可靠的結果並減少侵入性手術的需要，讓患者安心。液態切片和生物標記測定等非侵入性測試提供了一種侵入性較小的方法來監測癌症進展或復發，使患者能夠在最小的不適下控制疾病。從臨床角度來看，先進的診斷有助於風險分層，使腫瘤學家能夠識別需要積極治療的高風險患者和那些可以從不太密集的治療中受益的患者。隨著人們對前列腺癌認知的提高，採用先進的診斷工具正在成為患者照護的標準，這與個人化、以患者為中心的醫療保健的更廣泛趨勢相一致。

推動攝護腺癌診斷市場成長的因素有哪些？

前列腺癌診斷市場的成長受到多種因素的推動，包括人口老化、對前列腺癌認知的提高、診斷技術的進步以及精準醫療的趨勢。隨著全球前列腺癌高風險老年人口的增加，隨著醫療保健提供者努力提高早期檢測和介入率，對診斷的需求也在增加。這些人口變化強調了定期篩檢和風險評估，特別是在前列腺癌發病率高的國家。此外，宣傳宣傳活動鼓勵更多男性接受定期篩檢，有助於提高檢出率並增加對準確診斷的需求。

分子診斷和人工智慧等技術進步透過提高診斷程序的準確性、快速性和非侵入性，進一步推動市場成長。精準醫學計畫根據患者的遺傳特徵和癌症特徵優先考慮治療，也加速了對基於遺傳和生物標記的診斷的需求，從而實現更個人化的癌症治療方法。此外，監管機構對創新診斷工具的核准不斷增加，使臨床醫生和患者更容易使用它們。這些因素共同推動了前列腺癌診斷市場的強勁成長，並將其定位為對抗癌症的關鍵發展領域，因為醫療保健系統優先考慮早期檢測和個人化治療。

部分

檢驗類型（初步檢驗、確認檢驗）

受訪企業舉例（共34家）

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin SPA
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP22652

Global Prostate Cancer Diagnostics Market to Reach US$13.7 Billion by 2030

The global market for Prostate Cancer Diagnostics estimated at US$5.8 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. Preliminary Test, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$10.0 Billion by the end of the analysis period. Growth in the Confirmatory Test segment is estimated at 15.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 16.9% CAGR

The Prostate Cancer Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 16.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.0% CAGR.

Global Prostate Cancer Diagnostics Market - Key Trends & Drivers Summarized

What is Prostate Cancer Diagnostics, and Why is It Essential for Early Detection?

Prostate cancer diagnostics refers to the methods and technologies used to detect, diagnose, and monitor prostate cancer in men. These diagnostics are critical in identifying prostate cancer in its early stages, allowing for timely intervention and more effective treatment. The most common diagnostic methods include prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), and advanced imaging techniques like MRI and ultrasound. Additionally, biopsies are often used to confirm diagnosis and determine the stage of the cancer. Given that prostate cancer is one of the most common cancers among men, early and accurate diagnosis is essential to improving survival rates and managing treatment plans effectively.

The need for reliable diagnostics is increasingly important as awareness around prostate cancer grows, particularly among high-risk populations such as older men and those with a family history of the disease. By providing accurate and timely diagnoses, prostate cancer diagnostics not only help in initiating prompt treatment but also support monitoring of the disease's progression or recurrence after treatment. Early detection can lead to a wider range of treatment options and significantly reduce mortality rates. As the population ages and the prevalence of prostate cancer rises, demand for advanced diagnostic tools is increasing, making the prostate cancer diagnostics market a crucial component of modern healthcare.

How Are Technological Advancements Transforming Prostate Cancer Diagnostics?

Technological advancements in molecular diagnostics, imaging, and artificial intelligence (AI) are revolutionizing prostate cancer diagnostics, enabling more precise, less invasive, and faster diagnosis. Molecular diagnostic tests, such as genetic and biomarker testing, are increasingly used to detect specific genetic mutations or protein markers associated with prostate cancer. These tests help determine a patient’s risk level and may be used to guide personalized treatment decisions, allowing clinicians to tailor therapies based on the individual characteristics of the cancer. For example, tests like the PCA3 test and 4Kscore test use urine or blood samples to detect specific biomarkers, aiding in risk assessment and reducing the need for invasive biopsies.

Advanced imaging techniques, including multiparametric MRI and PET scans, provide highly detailed visuals that can detect prostate cancer with greater accuracy than traditional methods. These technologies allow for more precise targeting in biopsies and help in staging the cancer more accurately, which is essential for planning effective treatment. Additionally, AI and machine learning algorithms are now being used to analyze large datasets from imaging and genetic tests, enhancing diagnostic accuracy by identifying patterns that may be missed by human observation. AI-driven diagnostics are also proving valuable in risk assessment, predicting disease progression, and monitoring response to treatment. Together, these technologies are transforming the prostate cancer diagnostics market, enabling early detection, personalized care, and improved patient outcomes.

Why Are Patients and Clinicians Increasingly Adopting Advanced Prostate Cancer Diagnostics?

Patients and clinicians are increasingly adopting advanced prostate cancer diagnostics due to their potential for earlier and more accurate detection, reduced invasiveness, and personalized treatment options. Traditional diagnostics, such as PSA tests and DREs, have limitations in specificity and sensitivity, often leading to false positives or unnecessary biopsies. Advanced diagnostics, like molecular tests and MRI-targeted biopsies, provide more precise information on cancer risk and stage, enabling clinicians to make better-informed decisions about patient care. This is particularly important for patients with early-stage or slow-growing cancers, as it allows for active surveillance rather than immediate intervention, reducing potential side effects of overtreatment.

For patients, advanced diagnostics offer peace of mind by providing more reliable results and reducing the need for invasive procedures. Non-invasive tests, such as liquid biopsies and biomarker assays, offer a less intrusive way to monitor cancer progression or recurrence, allowing patients to manage their condition with minimal discomfort. From a clinical perspective, advanced diagnostics facilitate risk stratification, enabling oncologists to identify high-risk patients who require aggressive treatment and those who may benefit from less intensive approaches. As awareness around prostate cancer grows, the adoption of sophisticated diagnostic tools is becoming standard in patient care, aligning with a broader trend towards personalized and patient-centered healthcare.

What Factors Drive Growth in the Prostate Cancer Diagnostics Market?

The growth of the prostate cancer diagnostics market is driven by several factors, including the aging population, increased awareness of prostate cancer, advancements in diagnostic technology, and the trend towards precision medicine. With a growing global elderly population—who are at higher risk for prostate cancer—the demand for diagnostics is rising as healthcare providers strive to improve early detection and intervention rates. This demographic shift has intensified the focus on regular screenings and risk assessments, especially in countries with high prostate cancer prevalence. Additionally, increased awareness campaigns have encouraged more men to undergo routine screenings, contributing to greater detection rates and driving the need for accurate diagnostics.

Advancements in technology, such as molecular diagnostics and AI, are further propelling market growth by improving the accuracy, speed, and non-invasiveness of diagnostic procedures. Precision medicine initiatives, which prioritize treatments based on a patient’s genetic profile and cancer characteristics, have also accelerated demand for genetic and biomarker-based diagnostics, supporting a more personalized approach to cancer care. Moreover, regulatory agencies are increasingly approving innovative diagnostic tools, making them more accessible to clinicians and patients. As healthcare systems prioritize early detection and personalized treatment, these factors are collectively driving robust growth in the prostate cancer diagnostics market, positioning it as a key area of development in the fight against cancer.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Diagnostics market in terms of US$ Million by the following Test Type, and Geographic Regions/Countries:

Segments:

Test Type (Preliminary, Confirmatory)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin S.P.A.
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Prostate Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Prostate Cancer Globally Drives Demand for Advanced and Accurate Diagnostic Solutions
    • Increased Focus on Early Detection and Screening Spurs Market for Prostate-Specific Antigen (PSA) Testing
    • Growth in Personalized Medicine and Targeted Therapies Expands Demand for Genomic and Biomarker-Based Diagnostics
    • Advances in Imaging Technologies, Including MRI and PET Scans, Enhance Accuracy in Prostate Cancer Diagnosis
    • Increased Demand for Non-Invasive Testing Options Supports Development of Liquid Biopsy and Urine-Based Diagnostics
    • Growth in Awareness Campaigns and Screening Programs Elevates Market Demand for Accessible Diagnostic Tools
    • Expansion of AI and Machine Learning in Radiology Enhances Detection Accuracy and Reduces Diagnostic Errors
    • High Demand for Risk Stratification and Disease Progression Monitoring Fuels Use of Advanced Diagnostic Solutions
    • Rising Demand for Digital Pathology and Telemedicine Platforms Expands Accessibility of Prostate Cancer Diagnostics
    • Increased Focus on Minimally Invasive Biopsy Techniques Drives Adoption of MRI-Guided and Targeted Biopsies
    • Advances in Biomarker Discovery and Validation Strengthen Market for Predictive and Prognostic Testing
    • Growth of Immunohistochemistry (IHC) and Genetic Testing in Clinical Practice Expands Diagnostic Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preliminary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Confirmatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Prostate Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • JAPAN
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CHINA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • EUROPE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • FRANCE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • GERMANY
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • INDIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AFRICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030

IV. COMPETITION